The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Study to evaluate clinical effectiveness of low-dose oral interferons in treating chronic gingivostomatitis in cats, building upon VELDONA's history in animal health since 1985 Clinical trials are exp...
Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024 US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / A...
Proceeds for scaling up the company's VELDONA and AI Nose growth initiatives Convertible note convertible at $4.5 per share placed with existing shareholder SAN DIEGO, CA / ACCESSWIRE / May 7, 2024 / ...
Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of AI Nose-powered VOC-sensing...
Ainos (NASDAQ: AIMD ) stock is rocketing higher on Friday with heavy trading of the healthcare company's shares. This has more than 7 million shares of the company's stock changing hands as of this w...
Ainos (NASDAQ: AIMD ) stock is on the move Monday as the healthcare company's shares experienced heavy trading this morning. Ainos stock is experiencing strong pre-market trading on Monday as more th...
Updated Chemistry, Manufacturing, and Controls and Stability Test fulfill Ainos' development objectives Resolving the identified deficiencies will accelerate the timeline for Ainos' other clinical tri...
The follow-on funding is a draw down from the $10 million private placement agreement entered into September 25 2023. Use of proceeds include to advance planned VELDONA IND preparation and AI Nose VOC...
Ainos (NASDAQ: AIMD ) stock is rocketing higher on Friday alongside heavy trading of the healthcare company's shares. Investors will note that more than 8 million shares of AIMD stock have changed ha...